Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Top Pharma and Biotech firms Trust CompacT Automated Cell Culture to Generate their Cell Lines

Published: Friday, January 11, 2013
Last Updated: Friday, January 11, 2013
Bookmark and Share
See the System at SLAS on TAP Biosystems’ Booth #712 to find out why.

TAP Biosystems announced that with its latest installation of CompacT SelecT™, the technology remains the most widely adopted system for automated culture of adherent cell lines in T-flasks, used by major pharmaceutical and biotech companies worldwide. On Booth #712 at the Society for Laboratory Automation and Screening (SLAS) 2013 there is a unique opportunity to see the CompacT SelecT in action.

The CompacT SelecT systems installed in these leading companies offer parallel, aseptic cell culture processing in T75 and T175 flasks at any time of day or night, without scientists having to be present, thus providing a continuous supply of consistent quality cells for use in cell-based screening programmes.

The systems sited have each been tailored with a range of options which allow tasks such as automated cell imaging and analysis, control of culture conditions, media additions and passaging of immortalised, primary cells or stem cells. The cells are being used in applications including high throughput screening, lead optimisation, assay development, target identification and validation, as well as toxicity studies. The stem cell lines are being utilised to support research in therapeutic areas such as oncology and neurology.

The CompacT SelecT system will be on Booth #712 at SLAS2013. To book a demonstration time and find out more about the system options from TAP’s cell culture experts, please contact Matt Walker by email on matthew.walker@tapbiosystems.com.

Dr Dave Thomas, Product Manager at TAP Biosystems stated: "With the number of automated cell culture technologies increasing, we are pleased that our CompacT SelecT system has become the system of choice in the top pharma and biotech companies. Many of these firms now have multiple systems installed at their North American and European sites and a number are looking to place them in their new Asian drug discovery facilities.”

Thomas added: "The adoption of the CompacT SelecT systems by these leading companies is an excellent endorsement that the technology’s performance capabilities perfectly match their rigorous cell culture demands. Any pharma or biotech scientists looking for a proven and trusted method of consistently generating high quality cell lines should visit us on Booth #712 at SLAS, to discover how a CompacT SelecT system would help them to achieve reproducible results in their cell-based research and development programmes.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TAP Biosystems Presents New Data on 3D Cell Culture Research
Discussing the application of RAFT 3D models in oncology, toxicology and neuroscience cell-based screening programmes.
Monday, January 20, 2014
Scientific News
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
Microalgae Make a Splash in the UK Cosmeceutical Market
Scottish innovators have discovered an anti-viral and anti-inflammatory carbohydrate in microscopic algae (microalgae) which has huge potential to change the cosmetics market.
Mechanism of Tumor Suppressing Gene Uncovered
The most commonly mutated gene in cancer,p53, works to prevent tumor formation by keeping mobile elements in check that otherwise lead to genomic instability, UT Southwestern Medical Center researchers have found.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
Useful Colon Cancer Biomarker Discovered
Biomarker is detectable with simple, inexpensive test.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Seeing Hope
Gene therapy/drug combo restores some vision in mice with optic nerve injury.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!